

EMA/103735/2023

European Medicines Agency decision

P/0114/2023

of 13 April 2023

on the acceptance of a modification of an agreed paediatric investigation plan for satralizumab (Enspryng), (EMA-001625-PIP02-21-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0114/2023

of 13 April 2023

on the acceptance of a modification of an agreed paediatric investigation plan for satralizumab (Enspryng), (EMA-001625-PIP02-21-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0532/2021 issued on 3 December 2021,

Having regard to the application submitted by Roche Registration GmbH on 21 November 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 February 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for satralizumab (Enspryng), solution for injection, subcutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0154/2015 issued on 10 July 2015, including subsequent modifications thereof.

Article 3

This decision is addressed to Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany.

EMA/PDCO/912156/2022
Amsterdam, 24 February 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001625-PIP02-21-M01

Scope of the application

Active substance(s):

Satralizumab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of myasthenia gravis

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Roche Registration GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Roche Registration GmbH submitted to the European Medicines Agency on 21 November 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0532/2021 issued on 3 December 2021.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 3 January 2023.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of myasthenia gravis

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, subcutaneous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of myasthenia gravis

2.1.1. Indication(s) targeted by the PIP

Treatment of generalised myasthenia gravis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1 (WN42636) Randomised, double-blind, placebo-controlled trial to evaluate efficacy, safety, pharmacodynamics and pharmacokinetics of satralizumab in adolescents from 12 to less than 18 years of age (and adults) with generalised myasthenia gravis (gMG) Study 2 Open-label, uncontrolled trial to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability of satralizumab in children from 2 years to less than 12 years of age with generalised myasthenia gravis (gMG)
Extrapolation, modelling and simulation studies	Study 3 Modelling and simulation study to select the dose of satralizumab in

	children from 2 years to less than 12 years of age with generalised myasthenia gravis (gMG) through simulation Study 4 Extrapolation study to evaluate the use of satralizumab in the treatment of generalised myasthenia gravis (gMG) in adolescents from 12 years to less than 18 years of age Study 5 Extrapolation study to evaluate the use of satralizumab in the treatment of generalised myasthenia gravis (gMG) in children from 2 years to less than 12 years of age
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By April 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of neuromyelitis optica (NMO) or NMOSD.

Authorised indication(s):

- Enspryng is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive
 - Invented name(s): Enspryng
 - Authorised pharmaceutical form(s): Solution for injection
 - Authorised route(s) of administration: Subcutaneous use
 - Authorised via centralised procedure